CNA reported that CAR-T (chimeric antigen receptor T-cell) therapy, a new type of cell therapy for cancer, marketed commercially as Kymriah, has been approved for use in Singapore, providing another treatment option for patients with certain types of advanced blood cancers which are not in remission despite having gone through other forms of treatment.
CNA quoted A/Prof Allan Yeoh, Head and Senior Consultant, Division of Paediatric Haematology and Oncology, Khoo Teck Puat – National University Children's Medical Institute, National University Hospital, who shared that several studies have shown "significant improved patient outcomes with durable responses" with the new treatment. This gives hope to eligible patients, including paediatrics patients, in Singapore and the region who are seeking a different way to treat their cancer because previous treatments have not kept their cancer in remission, he added.
Commenting on how cancer treatment can be a heavy financial burden, A/Prof Yeoh said that patients in need may be eligible for financial support under various government assistance schemes and added that there is also the National University Cancer Institute Singapore Cancer Fund that caters to patients in need who may require additional support. Media ArticlesNUH in the NewsNCIS in the NewsNUHS in the News